Association of Site Volume and MitraClip Outcomes in Secondary Mitral Regurgitation

BACKGROUND: The number of sites performing transcatheter edge-to-edge repair (TEER) for secondary mitral regurgitation (SMR) has increased. Despite concerns that low-volume sites may have worse outcomes, data are limited on the association between site volume and TEER outcomes. OBJECTIVES: This study aimed to assess the association between site volume and mitral TEER outcomes in SMR. METHODS: The COAPT PAS (COAPT Post-Approval Study) included patients with SMR who underwent TEER with the MitraClip device from March 2019 to September 2020 following Food and Drug Administration approval. Sites were categorized by number of patients treated: low (≤25), medium (25-50), and high (>50). RESULTS: Of 5,000 patients, 2,632 were from low-, 1,527 from medium-, and 841 from high-volume sites. High-volume sites treated sicker patients with higher Society of Thoracic Surgeons scores and prior heart failure hospitalization rates. Procedures at low-volume sites had similar device implant rates (low: 97%, medium: 99%, high: 98%), used fewer number of clips (low: 1.4 ± 0.6, medium: 1.5 ± 0.6, high: 1.6 ± 0.7 clips, P < 0.001), and had longer device (low: 68 ± 55, medium: 56 ± 53, high: 57 ± 42 min, P < 0.001) and procedure times (low: 153 ± 67, medium: 131 ± 59, high: 128 ± 56 min, P < 0.001). Technical success was comparable (low: 93%, medium: 94%, high: 95%, P = 0.92). MR reduction to ≤2+ and ≤1+ was also similar. There was no difference in heart failure hospitalization (low: 19%, medium: 18%, high: 20%, P = 0.50) or all-cause mortality (low: 23%, medium: 21%, high: 20%, P = 0.27). CONCLUSIONS: Technical success, MR reduction, and 1-year clinical outcomes were comparable across volume strata during the early adoption phase, without significant differences between low- and high-volume centers.

Authors

Institutions

Publication Details

Journal
JACC Advances
Published
2026-11-14
DOI
https://doi.org/10.1016/j.jacadv.2026.103501
Primary Topic
Cardiac Valve Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of Site Volume and MitraClip Outcomes in Secondary Mitral Regurgitation

Vinod H. Thourani, Raj R. Makkar, Kashish Goel, Hursh Naik et al.
1 links
JACC Advances
Cardiac Valve Diseases and Treatments
article

Association of Site Volume and MitraClip Outcomes in Secondary Mitral Regurgitation

Vinod H. Thourani, Raj R. Makkar, Kashish Goel, Hursh Naik, Brian R. Lindman, JoAnn Lindenfeld, Janani Aiyer, Paul Mahoney, Colin Barker, Satya Atmakuri, Rong Huang, M. Andrew Morse
article en

Abstract

BACKGROUND: The number of sites performing transcatheter edge-to-edge repair (TEER) for secondary mitral regurgitation (SMR) has increased. Despite concerns that low-volume sites may have worse outcomes, data are limited on the association between site volume and TEER outcomes. OBJECTIVES: This study aimed to assess the association between site volume and mitral TEER outcomes in SMR. METHODS: The COAPT PAS (COAPT Post-Approval Study) included patients with SMR who underwent TEER with the MitraClip device from March 2019 to September 2020 following Food and Drug Administration approval. Sites were categorized by number of patients treated: low (≤25), medium (25-50), and high (>50). RESULTS: Of 5,000 patients, 2,632 were from low-, 1,527 from medium-, and 841 from high-volume sites. High-volume sites treated sicker patients with higher Society of Thoracic Surgeons scores and prior heart failure hospitalization rates. Procedures at low-volume sites had similar device implant rates (low: 97%, medium: 99%, high: 98%), used fewer number of clips (low: 1.4 ± 0.6, medium: 1.5 ± 0.6, high: 1.6 ± 0.7 clips, P < 0.001), and had longer device (low: 68 ± 55, medium: 56 ± 53, high: 57 ± 42 min, P < 0.001) and procedure times (low: 153 ± 67, medium: 131 ± 59, high: 128 ± 56 min, P < 0.001). Technical success was comparable (low: 93%, medium: 94%, high: 95%, P = 0.92). MR reduction to ≤2+ and ≤1+ was also similar. There was no difference in heart failure hospitalization (low: 19%, medium: 18%, high: 20%, P = 0.50) or all-cause mortality (low: 23%, medium: 21%, high: 20%, P = 0.27). CONCLUSIONS: Technical success, MR reduction, and 1-year clinical outcomes were comparable across volume strata during the early adoption phase, without significant differences between low- and high-volume centers.

JACC AdvancesVol. 5(12)
Cedars-Sinai Medical Center (US), St. Joseph's Hospital and Medical Center (US), East Carolina University (US), St. Joseph's Hospital (US), Vanderbilt University Medical Center (US)
Abbott Vascular
Good health and well-being
Cardiac Valve Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon